DelveInsight Blogs Sitemap

All Posts in this category
S.No. Product Name Actions
1 Sanofi bets $3.2B on mRNA; Marinus signs $30M deal with Orion; Mestag with $45M seed; Moderna secures fast track designation Visit Post
2 Alarming Growth of Chronic Respiratory Diseases (CRDs) and Their Prolonged Impact on the Quality of Life Visit Post
3 InnoCare's Trial In China; Sanofi/GSK COVID-19 Vaccine; Apellis’s Empaveli for PNH; LianBio, Landos Collab Visit Post
4 Asthma: Rising Prevalence And The Key Challenges In The Management Visit Post
5 Abingworth & Alebund's Finacial Closing; Pfizer/BioNTech COVID-19 Vaccine Expanded Use; Biogen and Capsigen Deal Visit Post
6 Pfizer hit by DMD delay & halts BCMA trials; Sarepta's drug shows promise in Phase II; Human organ chips enable COVID-19 drug repurposing; AbCellera takes new antibody into clinic Visit Post
7 Ocugen-Bharat Biotech’s Covaxin Against B.1.617 Corona Variant; uniQure Shares; J&J Covid Vaccine; Sanofi-Moderna COVID Vaccine Deal Visit Post
8 Cystic Fibrosis Market: A Rapidly Expanding Playing Field for Mid-Cap Pharma Visit Post
9 Plaque psoriasis drug outshines in phase III trial; Immunovant announces pause in trial of IMVT-1401; Prothena brings AL amyloidosis drug back; Canon Medical expands its MRI AI programs Visit Post
10 Chronic Refractory Cough Market and the Monopoly of the Over-The-Counter Drugs Visit Post
11 Ikena bags $120M; Terns raises $87M for NASH; Ribometrix Genentech Collaboration; Hologic acquires Biotheranostics Visit Post
12 Unmet Needs and Emerging Trends in the Acute Respiratory Distress Syndrome Market Landscape Visit Post
13 Novartis taps Molecular Partners to combat COVID-19; GSK culls phase 2 asthma drug; Exact Sciences acquires Thrive for $ 2.15 B; EQRx-CStone's deal for checkpoint inhibitors Visit Post
14 Gilead's remdesivir trials; F2G raises $60.8M; Cancer immunotherapy research updates; Celleron gains rights to Roche's cancer drug Visit Post
15 Infectious Diseases That Possess Significant Challenge To Humans Health Visit Post
16 Merck; Bayer; Shionogi set to showcase their candidates indicated for Chronic RefractoryCough in the ATS Virtual Conference Visit Post
17 Zydus starts Phase II COVID-19 vaccine trial; Taysha raises $95M; FDA declines DBV's peanut allergy patch; Combating COVID-19 with decoy target Visit Post
18 In The Global Race For The COVID-19 Vaccine, India Stands As A Strong Player Visit Post
19 AZ shows positive results for its COVID-19 vaccine; Synairgen offers a new approach to address COVID; GSK, CureVac forms mRNA strategic partnership Visit Post
20 Merck, Dewpoint's HIV Pipeline; Pfizer, BioNTech 's COVID-19 Vaccines; Roche’s Tecentriq- Avastin Duo Failure in Ovarian Cancer Visit Post
21 The Most Promising COVID-19 Vaccine Candidates In The Pipeline To Watch Out For Visit Post
22 Regeneron's cocktail antibody, REGN-COV2; J&J's manufacturing-spree; ObsEva's Yselty top-line studies Visit Post
23 The Increasing Global Burden of Cytomegalovirus Seroprevalence Visit Post
24 HCQ/ CQ failure; AZ/ Catalent’s deal; Sinovac’s CoronaVac and Lilly’s Olumiant trial results Visit Post
25 AbbVie & Genmab’s Collaboration; Lilly's antisense neuro deal; COVID-19 treatment updates; Roche’s partnership with Innovent; Visit Post
26 Alnylam’s lumasiran results; AZ’s oncology drug; Astellas Roxadustat; Evotec’s partnership with ABL Visit Post
27 Eli Lilly's COVID-19 Antibody trial; Approval for Oriahnn; Gilead's Remdesivir Clinical Trials result; Russia approves Avifavir to treat Covid-19 Visit Post
28 Algernon's NP-120; FDA nod to 4DMedical tool; SaNOtize's NORSTM trial; Pole's capital increase Visit Post
29 Keeping a track on COVID-19 through Wearable Technology Visit Post
30 Moderna's COVID-19 Vaccine; Quidel's Lyra gets EUA from FDA; Neurotrope and Metuchen Pharma Announced Merger Agreement; FDA Approval to Rucaparib; Visit Post
31 Security Breach: A Growing Concern For The Healthcare Industry Visit Post
32 Will there be a second wave of coronavirus? Visit Post
33 Telehealth: Opportunities and Hurdles in Virtual Healthcare Market Visit Post
34 In the race to fight SARS-CoV-2: Merck, ISB; ViiV; Genalyte gears up Visit Post
35 Potential Diagnostic solutions that may significantly contribute to COVID-19 detection Visit Post
36 COVID19 pipeline advances as Novartis begins phase III trial of hydroxychloroquine; and advancements in RCC, and HER2 positive breast cancer market Visit Post
37 Novel coronavirus crumbles down as soon as it lands on copper Visit Post
38 Supply shortage: Why ventilators are in demand amid the Coronavirus crisis Visit Post
39 In the fight against COVID-19 – Lilly with Olumiant, Gilead with remdesivir, Rutgers with testing kit Visit Post
40 Is Hydroxychloroquine the answer to all the COVID-19 questions? Visit Post
41 AstraZeneca targets for COVID-19 antibody trial; Arrakis, Roche team up; GSK, AstraZeneca launch testing lab, U.S. government funds OraSure Visit Post
42 COVID-19 crisis can prove to be a catalyst for Artificial Intelligence in Healthcare Visit Post
43 World Health Day Visit Post
44 Telemedicine: Can it be the future of healthcare? Visit Post
45 J&J's COVID-19 Vaccine; GigaGen COVID-19 therapy; FDA approved Abbott's POC test; Cobra Bio raises $ 3.3 M Visit Post
46 Realm of Pandemics: Were we prepared then? Are we prepared now? Will we be ever prepared? Visit Post
47 FDA permits COVID-19 treatment, Roche's antibiotics pact, Moderna's vaccine, FDA permits Remdesivir, ReCode needs USD 80 Million Visit Post
48 Thermo’s investment; Biohaven’s vazegepant Phase III trial; Cumberland’s aid Visit Post
49 J&J collaborates with BARDA; Virus kills pancreatic cancer cells; ALX raises USD 105 million for CD47 drug Visit Post
50 The epidemic now has a name: COVID-19 Visit Post
51 Immune cells for age-related diseases; Regeneron's antibody for 2019-nCoV; FDA nods for hydrogel injection Visit Post
52 Potential of Digital therapeutics and increasing CVDs Visit Post
53 Chronic Refractory Cough Market landscape: A new approach to treating cough Visit Post
54 World COPD Day Visit Post
55 Is Air Pollution a driver in COPD Treatment Market? Visit Post
56 FDA approval to AZ’s Farxiga for heart failure; GSK divests two travel vaccines to Bavarian Nordic; New breakthrough therapy for Cystic Fibrosis Visit Post
57 Cystic Fibrosis Drug Market: Emerging drugs that may improve lung infections Visit Post
58 World Lung Day Visit Post
59 Idiopathic Pulmonary Fibrosis Market Landscape and Forecast Visit Post
60 Idiopathic Pulmonary Fibrosis –Scarring For A Lifetime Visit Post
62 Notizia Visit Post
63 Pulmonary Arterial Hypertension Therapies Visit Post
64 Ginkgo to buy mining platform; Vertex, Kymera collaborate; ArcherDX nets $60M; Bayer to invest $150M Visit Post
65 NO SMOKING DAY Visit Post
66 Notizia Visit Post
68 Novartis signs; Sosei passes; Amgen remunerates; J&J remunerates for RSV drug Visit Post
69 Notizia Visit Post
70 Notizia Visit Post
71 4D Molecular Therapeutics raises; Arvinas slates for IPO; Sutro ruminates for $ 75M; Emergent BioSolutions remunerates Narcan maker Visit Post
72 Clinical Visit Post
73 AbbVie Receives Approval; Kymriah Approved; Shire Gets USFDA Approval; NICE Rejects; Bristol-Myers Squibb’s Opdivo; Eisai and Merck Get USFDA Approval Visit Post
74 Idiopathic Pulmonary Fibrosis (IPF) – When to start and what is coming in the race to treat the deadlier constricts…. Visit Post
75 NOTIZIA Visit Post
76 Biohaven’s trial ; GSK integrates; FDA Approval; Phase III trial Visit Post
77 AZ’s benralizumab; Sanofi, Regeneron set; Nordisk preps; European countries offer Visit Post
78 Valeant's asset-sale; Sanofi coughs up $19.8M; Sanofi's Genzyme; India's Alkem; GSK’s inhalers Visit Post
79 Business Cocktail Visit Post
80 Chronic Obstructive Pulmonary Disorder Visit Post
81 Chronic Obstructive Pulmonary Disease (COPD): Scenario Visit Post
82 Idiopathic Pulmonary Fibrosis: Recent Scenario Visit Post
83 AstraZeneca’s new Asthma Drug Aces Phase III trial Visit Post
84 BI & Duke Clinical Research Institute have expansion; BioInvent Inks Mfg. Pact; Elite Pharma, SunGen Pharma in Development & License Deal; Boehringer and Saniona Develop new Compounds; BioLineRx and I-Bridge Capital Establish; Alliance between Harvard and Tata Companies; Innovative Targeting Solutions and Johnson & Johnson Innovation collaborate Visit Post
85 Idiopathic pulmonary fibrosis (IPF) - Market Insights, Epidemiology and Market Forecast-2020 Visit Post
86 Small interfering RNA (siRNA) Therapeutics Visit Post
87 DelveInsight’s Respiratory disorders based Gene Therapy Reports Visit Post